X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN LTD GLENMARK PHARMA/
LUPIN LTD
 
P/E (TTM) x 12.2 19.9 61.3% View Chart
P/BV x 3.2 2.7 119.5% View Chart
Dividend Yield % 0.4 0.9 40.3%  

Financials

 GLENMARK PHARMA   LUPIN LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
LUPIN LTD
Mar-17
GLENMARK PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs9931,750 56.7%   
Low Rs7291,384 52.7%   
Sales per share (Unadj.) Rs325.5387.4 84.0%  
Earnings per share (Unadj.) Rs39.356.6 69.4%  
Cash flow per share (Unadj.) Rs48.776.8 63.3%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.20.5 48.5%  
Book value per share (Unadj.) Rs159.2298.9 53.3%  
Shares outstanding (eoy) m282.17451.58 62.5%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x2.64.0 65.4%   
Avg P/E ratio x21.927.7 79.2%  
P/CF ratio (eoy) x17.720.4 86.8%  
Price / Book Value ratio x5.45.2 103.2%  
Dividend payout %5.113.2 38.4%   
Avg Mkt Cap Rs m242,991707,513 34.3%   
No. of employees `00013.016.8 77.2%   
Total wages/salary Rs m16,40828,495 57.6%   
Avg. sales/employee Rs Th7,083.910,418.3 68.0%   
Avg. wages/employee Rs Th1,265.41,697.0 74.6%   
Avg. net profit/employee Rs Th855.11,523.0 56.1%   
INCOME DATA
Net Sales Rs m91,857174,943 52.5%  
Other income Rs m3741,065 35.1%   
Total revenues Rs m92,230176,008 52.4%   
Gross profit Rs m20,36744,931 45.3%  
Depreciation Rs m2,6449,122 29.0%   
Interest Rs m2,3731,525 155.6%   
Profit before tax Rs m15,72435,349 44.5%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8279,785 39.1%   
Profit after tax Rs m11,08825,575 43.4%  
Gross profit margin %22.225.7 86.3%  
Effective tax rate %24.327.7 87.9%   
Net profit margin %12.114.6 82.6%  
BALANCE SHEET DATA
Current assets Rs m68,746119,542 57.5%   
Current liabilities Rs m27,02761,206 44.2%   
Net working cap to sales %45.433.3 136.2%  
Current ratio x2.52.0 130.2%  
Inventory Days Days8576 111.8%  
Debtors Days Days9690 106.3%  
Net fixed assets Rs m24,132131,660 18.3%   
Share capital Rs m282903 31.2%   
"Free" reserves Rs m44,643134,073 33.3%   
Net worth Rs m44,925134,976 33.3%   
Long term debt Rs m45,36356,478 80.3%   
Total assets Rs m117,639266,073 44.2%  
Interest coverage x7.624.2 31.5%   
Debt to equity ratio x1.00.4 241.3%  
Sales to assets ratio x0.80.7 118.8%   
Return on assets %11.410.2 112.3%  
Return on equity %24.718.9 130.3%  
Return on capital %19.119.3 99.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15281,885 68.6%   
Fx outflow Rs m8,08421,506 37.6%   
Net fx Rs m48,06860,378 79.6%   
CASH FLOW
From Operations Rs m6,57441,148 16.0%  
From Investments Rs m-7,124-25,287 28.2%  
From Financial Activity Rs m5,4324,332 125.4%  
Net Cashflow Rs m1,99220,193 9.9%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS